Scabies in infants and children - a narrative review.
Anca E ChiriacAdriana DiaconeasaRaluca MiulescuAnca E ChiriacUwe WollinaPublished in: European journal of pediatrics (2024)
Scabies is a human ectoparasitosis caused by Sarcoptes scabei var. hominis. World-wide around 300 million patients are affected. Infants and children have the highest incidence rates. Poverty and overcrowding are social factors contributing to a higher risk of transmission and treatment failure. The leading symptom of the infestation is itch. Complications are bacterial infections that are responsible for mortality. Diagnosis is clinical. Non-invasive imaging technologies like dermoscopy can be used. Polymerase chain reaction (PCR) is less sensitive and specific than microscopy of skin scrapings. Treatment of choice is topical permethrin 5%. Ivermectin is the only oral drug FDA-approved for scabies. It should be used in cases non-responsive to topical therapy and in case of high number of infested patients in addition to topical therapy. Pseudo-resistance to treatment is not uncommon. New drugs are on the horizon. What is Known: • Pruritus is the leading symptom causing sleep disturbances and scratching with the risk of secondary bacterial infections. • Treatment failure is related to inappropriate application of topical drugs and asymptomatic family members. What is New: • COVID-19 pandemic and migration are contributing to an increased incidence of scabies. • New compounds to treat scabies are on the horizon.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- risk factors
- young adults
- endothelial cells
- peritoneal dialysis
- wound healing
- stem cells
- emergency department
- high resolution
- mesenchymal stem cells
- prognostic factors
- patient reported
- single molecule
- high speed
- optical coherence tomography
- cardiovascular events
- high throughput
- patient reported outcomes
- sleep quality
- decision making
- smoking cessation